MX2019003981A - Formulaciones para la administracion de eflornitina. - Google Patents

Formulaciones para la administracion de eflornitina.

Info

Publication number
MX2019003981A
MX2019003981A MX2019003981A MX2019003981A MX2019003981A MX 2019003981 A MX2019003981 A MX 2019003981A MX 2019003981 A MX2019003981 A MX 2019003981A MX 2019003981 A MX2019003981 A MX 2019003981A MX 2019003981 A MX2019003981 A MX 2019003981A
Authority
MX
Mexico
Prior art keywords
eflornithine
glioma
pharmaceutical compositions
present
agent
Prior art date
Application number
MX2019003981A
Other languages
English (en)
Inventor
Yam Noymi
A Levin Victor
Vakoula Alexander
Original Assignee
Orbus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbus Therapeutics Inc filed Critical Orbus Therapeutics Inc
Publication of MX2019003981A publication Critical patent/MX2019003981A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La eflornitina es un agente que se puede usar para tratar el glioma, especialmente el glioma de grado II o grado III de la OMS, como el glioma anaplasico; la eflornitina puede suprimir o prevenir las mutaciones en el glioma, lo que puede hacer que el glioma progrese a un grado mas alto; la presente invención describe composiciones farmacéuticas que contienen eflornitina o un derivado, analogo o profarmaco de la misma; las composiciones farmacéuticas pueden prepararse en varias formas de dosificación y pueden contener otro agente terapéuticamente activo o un agente que mejore la actividad terapeutica de la eflornitina o el derivado, análogo o profarmaco de la misma; la presente invención también describe un kit que incluye formas de dosificación de composiciones farmacéuticas de acuerdo con la presente invención.
MX2019003981A 2016-10-06 2017-09-29 Formulaciones para la administracion de eflornitina. MX2019003981A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404981P 2016-10-06 2016-10-06
PCT/US2017/054450 WO2018067401A1 (en) 2016-10-06 2017-09-29 Formulations for administration of eflornithine

Publications (1)

Publication Number Publication Date
MX2019003981A true MX2019003981A (es) 2019-06-10

Family

ID=61831551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003981A MX2019003981A (es) 2016-10-06 2017-09-29 Formulaciones para la administracion de eflornitina.

Country Status (11)

Country Link
US (3) US10786470B2 (es)
EP (1) EP3523274A4 (es)
JP (2) JP7262118B2 (es)
KR (2) KR102473491B1 (es)
CN (2) CN110191876A (es)
AU (2) AU2017339781B2 (es)
CA (2) CA3038530A1 (es)
IL (1) IL265856A (es)
MX (1) MX2019003981A (es)
NZ (2) NZ752894A (es)
WO (1) WO2018067401A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ752894A (en) 2016-10-06 2023-05-26 Orbus Therapeutics Inc Formulations for administration of eflornithine
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
ES2920428T3 (es) 2018-03-08 2022-08-03 Applied Molecular Transport Inc Constructos de administración derivados de toxinas para la administración oral
GB2591396B (en) * 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
EP3836899A2 (en) * 2018-08-18 2021-06-23 FTF Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
CN109528667A (zh) * 2018-12-19 2019-03-29 石家庄海瑞药物科技有限公司 一种达克替尼药物组合物及其制备方法
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021191928A1 (en) * 2020-03-23 2021-09-30 Navin Saxena Research & Technology Pvt. Ltd. Eflornithine composition and dosage forms for the treatment of viral infection

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330559A (en) * 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US5614557A (en) 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US5851537A (en) 1996-02-02 1998-12-22 Cancer Technologies, Inc. Topical application of α-DFMO for preventing skin cancer
AU5200098A (en) * 1996-11-01 1998-05-29 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6646149B1 (en) 1997-07-15 2003-11-11 Nicolaas M. J. Vermeulin Polyamine analogues as therapeutic and diagnostic agents
EP1067919A1 (en) 1998-03-28 2001-01-17 THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA Dfmo and sulindac combination in cancer chemoprevention
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
JP2002533416A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 新形成の治療における組み合わせ治療としてのシクロオキシゲナーゼ−２インヒビターおよび一つまたはそれ以上の抗腫瘍薬の使用方法
US6199698B1 (en) * 1999-12-03 2001-03-13 Alusuisse Technology & Management, Ltd. Pharmaceutical packaging with separation means
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) * 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
US6630511B2 (en) 2000-08-01 2003-10-07 Rolland F. Hebert Water-soluble salts of 2-difluoromethyl-2,5-diaminopentanoic acid (DFMO)
US6653351B2 (en) * 2001-08-13 2003-11-25 Board Of Regents, The University Of Texas System Adjuvant chemotherapy for anaplastic gliomas
US7374770B2 (en) * 2001-08-15 2008-05-20 Skinmedica, Inc. Topical composition for follicular delivery of an ornithine decarboxylase inhibitor
US20030053793A1 (en) * 2001-09-20 2003-03-20 Peter Holzmann Analog/digital recording and playback system and related method
US6998502B1 (en) * 2002-09-05 2006-02-14 Sabinsa Corporation Convenient process of manufacture for difluoromethylornithine and related compounds
US6936318B2 (en) * 2003-09-17 2005-08-30 Reynolds Metals Company No tear pharmaceutical pouch
US8673366B2 (en) 2004-06-14 2014-03-18 Kareem I. Batarseh Chemotherapeutic and prophylactic pharmaceutical compositions
SE0401871D0 (sv) 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
EP1924327A2 (en) * 2005-04-15 2008-05-28 Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
MX346530B (es) 2005-06-15 2017-03-22 Cardiome Pharma Corp Procedimiento sintético para la preparación de compuestos de éter aminociclohexílico.
WO2007075673A1 (en) 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
US20070246057A1 (en) 2006-04-20 2007-10-25 Muller Sigfrid A Ear treatment for excess hair
US8633249B2 (en) 2008-09-02 2014-01-21 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
MX359574B (es) 2008-09-03 2018-10-03 Univ Johns Hopkins Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno.
US20100120727A1 (en) * 2008-11-12 2010-05-13 Kyphia Pharmaceuticals, Inc. Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof
CN101898978A (zh) * 2009-05-31 2010-12-01 徐锋 依氟鸟氨酸前药和偶合物及其使用方法
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
PT2794611T (pt) 2011-12-22 2017-12-06 Gilead Sciences Inc Pirazolo[1,5-a]pirimidinas como agentes antivirais
LT2838900T (lt) 2012-04-17 2019-11-11 Gilead Sciences Inc Junginiai ir būdai, skirti priešvirusinei terapijai
WO2016130918A1 (en) * 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
WO2017075576A1 (en) * 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
US10973790B2 (en) * 2015-10-30 2021-04-13 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
US20190133985A1 (en) 2016-03-24 2019-05-09 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
US20170273926A1 (en) 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
NZ752894A (en) 2016-10-06 2023-05-26 Orbus Therapeutics Inc Formulations for administration of eflornithine
US10945981B2 (en) * 2019-05-17 2021-03-16 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis

Also Published As

Publication number Publication date
KR102592801B1 (ko) 2023-10-20
EP3523274A4 (en) 2020-05-13
NZ752894A (en) 2023-05-26
IL265856A (en) 2019-06-30
KR102473491B1 (ko) 2022-12-05
AU2017339781B2 (en) 2022-03-17
WO2018067401A1 (en) 2018-04-12
EP3523274A1 (en) 2019-08-14
CN110191876A (zh) 2019-08-30
US11439612B2 (en) 2022-09-13
CN117530943A (zh) 2024-02-09
AU2017339781A1 (en) 2019-05-16
JP2019534265A (ja) 2019-11-28
AU2022202162A1 (en) 2022-04-21
US20200138758A1 (en) 2020-05-07
US20210038549A1 (en) 2021-02-11
CA3176428A1 (en) 2018-04-12
JP2023040218A (ja) 2023-03-22
KR20220162869A (ko) 2022-12-08
KR20190084960A (ko) 2019-07-17
NZ792518A (en) 2023-04-28
JP7262118B2 (ja) 2023-04-21
US10786470B2 (en) 2020-09-29
US20230338317A1 (en) 2023-10-26
CA3038530A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
MX2019003981A (es) Formulaciones para la administracion de eflornitina.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
PH12018501920A1 (en) Bromodomain inhibitors
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
EA036036B1 (ru) Композиции, содержащие циклоспорин
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
MX2022013450A (es) Formulaciones farmaceuticas.
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MY197595A (en) Alkyl dihydroquinoline sulfonamide compounds
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2019012522A (es) Compuestos y metodos terapeuticos.
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
PH12017501668A1 (en) Bace1 inhibitors
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2019008847A (es) Profarmacos de cisteamina.
MX2018013569A (es) Composicion valeriana y metodos relacionados.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12019501049A1 (en) Pharmaceutical composition containing palonosetron as active ingredient
MX2017014471A (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.